The new kit increases the assay range and contains changed components for reduced manufacturing costs and improved margins.
Axis-Shield CEO Ian Gilham said the clearance of their new anti-CCP assay by the FDA will broaden their offering of diagnostics in areas of clinical need, both to the laboratory market and at the point of care.
